mRNA CAR-γδ-T Cell Platform
Cancer (unspecified)
Pre-clinicalActive
Key Facts
About PhosphoGam
PhosphoGam is a private, preclinical-stage biotech based in Durham, NC, pioneering a novel approach to allogeneic CAR-T. Its core innovation is a proprietary small-molecule platform for the limitless, consistent, and economical expansion of fit γδ-T cells from healthy donors, which are then engineered using non-viral mRNA electroporation to create CAR-T products. The company's strategy emphasizes re-dosing, enhanced tumor-homing, and transient persistence to improve efficacy and safety while achieving massive scale. Backed by a leading biotech VC, PhosphoGam aims to address the major limitations of cost, scale, and solid tumor penetration in current cell therapies.
View full company profileTherapeutic Areas
Other Cancer (unspecified) Drugs
| Drug | Company | Phase |
|---|---|---|
| Allogeneic CAR-NK Platform Product | Simnova Biotherapeutics | Phase 1 |
| CAR-engineered NK cells | Glycostem | Pre-clinical |
| Lead Universal CAR-T Candidate | Allogenica | Pre-clinical |
| ADU-1805 | Sairopa | Preclinical |
| PSC-derived NK Cells | HebeCell | Pre-clinical |
| R-5780 | Rise Therapeutics | Phase 1 |
| Dendritic Cell-Based Cancer Vaccines | Celica Biomedical | Pre-clinical |
| PD-1/VEGF Program | OncoC4 | Not Disclosed |
| FC001 | FerroptoCure | Phase 1 |
| FC004 | FerroptoCure | Preclinical |
| Oncology Drug Delivery | Sporegen | Pre-clinical |